FDA starts speedy review of Amgen’s lung cancer BiTE therapy

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

Submitted by admin on December 14, 2023 - 9:34am
Source: 
Pharmaphorum
News Tags: 
Amgen
tarlatamab
small cell lung cancer
bispecifics
BiTE
solid tumors
Headline: 
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
snippet: 

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumors.

Do Not Allow Advertisers to Use My Personal information